全文获取类型
收费全文 | 692篇 |
免费 | 36篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 45篇 |
妇产科学 | 10篇 |
基础医学 | 44篇 |
口腔科学 | 17篇 |
临床医学 | 73篇 |
内科学 | 166篇 |
皮肤病学 | 7篇 |
神经病学 | 47篇 |
特种医学 | 56篇 |
外科学 | 99篇 |
综合类 | 10篇 |
预防医学 | 36篇 |
眼科学 | 43篇 |
药学 | 23篇 |
肿瘤学 | 32篇 |
出版年
2021年 | 9篇 |
2020年 | 10篇 |
2019年 | 10篇 |
2018年 | 12篇 |
2017年 | 14篇 |
2016年 | 16篇 |
2015年 | 16篇 |
2014年 | 17篇 |
2013年 | 28篇 |
2012年 | 39篇 |
2011年 | 40篇 |
2010年 | 23篇 |
2009年 | 25篇 |
2008年 | 42篇 |
2007年 | 37篇 |
2006年 | 49篇 |
2005年 | 39篇 |
2004年 | 27篇 |
2003年 | 21篇 |
2002年 | 19篇 |
2001年 | 8篇 |
2000年 | 8篇 |
1999年 | 18篇 |
1998年 | 11篇 |
1997年 | 10篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 16篇 |
1993年 | 10篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 6篇 |
1988年 | 12篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 13篇 |
1984年 | 5篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1976年 | 6篇 |
1972年 | 2篇 |
1971年 | 5篇 |
1969年 | 2篇 |
1965年 | 3篇 |
1963年 | 4篇 |
1962年 | 2篇 |
1956年 | 2篇 |
排序方式: 共有730条查询结果,搜索用时 15 毫秒
81.
82.
北京地区心血管病门诊人群勃起功能障碍患病率调查 总被引:5,自引:0,他引:5
目的:了解北京地区心血管病门诊人群勃起功能障碍(ED)的患病率及影响因素。方法;共入选6848例到心血管门诊就诊的年龄大于等于35岁的男性患。调查采用问卷形式。根据患的自我评价诊断ED。结果:在本调查中,ED的总患病率为84.5%,其中轻度、中度和重度ED分别占28.5%、41.8%和14.2%。该人群ED的知晓率为24.1%,治疗率3.2%。老年、糖尿病、心脏病(心绞痛、心肌梗死)、高胆固醇血症、抑郁症和排尿困难是影响ED患病率的重要因素。饮酒和受教育程度对ED也有一定的影响。合并ED的心血管疾病及危险因素的患对总体生活和性生活满意的比例明显下降,但对勃起功能的关注程度却增高。结论:在心血管病门诊人群中ED是常见病,是一个重要的健康问题。 相似文献
83.
Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link 总被引:5,自引:4,他引:5
Griscelli-Bennaceur A; Gluckman E; Scrobohaci ML; Jonveaux P; Vu T; Bazarbachi A; Carosella ED; Sigaux F; Socie G 《Blood》1995,85(5):1354-1363
The association of paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA) raises the yet unresolved questions as to whether these two disorders are different forms of the same disease. We compared two groups of patients with respect to cytogenetic features, glycosylphosphatidylinositol (GPI)-linked protein expression, protein C/protein S/thrombomodulin/antithrombin III activity, and PIG-A gene expression. The first group consisted of eight patients with PNH (defined as positive Ham and sucrose tests at diagnosis), and the second, 37 patients with AA. Twelve patients with AA later developed a PNH clone. Monoclonal antibodies used to study GPI-linked protein expression (CD14 [on monocytes], CD16 [on neutrophils], CD48 [on lymphocytes and monocytes], CD67 [on neutrophils and eosinophils], and, more recently, CD55, CD58, and CD59 [on erythrocytes]) were also tested on a cohort of 20 normal subjects and five patients with constitutional AA. Ham and sucrose tests were performed on the same day as flow- cytometric analysis. Six of 12 patients with AA, who secondarily developed a PNH clone, had clinical symptoms, while all eight patients with PNH had pancytopenia and/or thrombosis and/or hemolytic anemia. Cytogenetic features were normal in all but two patients. Proteins C and S, thrombomodulin, and antithrombin III levels were within the normal range in patients with PNH and in those with AA (with or without a PNH clone). In patients with PNH, CD16 and CD67 expression were deficient in 78% to 98% of the cells and CD14 in 76% to 100%. By comparison, a GPI-linked defect was detected in 13 patients with AA, affecting a mean of 32% and 33% of CD16/CD67 and CD14 cell populations, respectively. Two of three tested patients with PNH and 1 of 12 patients with AA had a defect in the CD48 lymphocyte population. In a follow-up study of our patient cohort, we used the GPI-linked molecules on granulocytes and monocytes investigated earlier and added the study of CD55, CD58, and CD59 on erythrocytes. Two patients with PNH and 14 with AA were studied for 6 to 13 months after the initial study. Among patients with AA, four in whom no GPI-anchoring defect was detected in the first study had no defect in follow-up studies of all blood-cell subsets (including erythrocytes). Analysis of granulocytes, monocytes, and erythrocytes was performed in 7 of 13 AA patients in whom affected monocytes and granulocytes were previously detected. A GPI-anchoring defect was detected on erythrocytes in five of six.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
84.
Jeanne Palmer Xiaoyu Chai Paul J Martin Daniel Weisdorf Yoshihiro Inamoto Joseph Pidala Madan Jagasia Steven Pavletic Corey Cutler Georgia Vogelsang Sally Arai Mary ED Flowers Stephanie J Lee 《Haematologica》2015,100(5):690-695
Failure-free survival, defined as the absence of relapse, non-relapse mortality or addition of another systemic therapy, has been proposed as a potential endpoint for clinical trials, but its use has only been reported for single-center studies. We measured failure-free survival in a prospective observational cohort of patients (n=575) with both newly diagnosed and existing chronic graft-versus-host disease from nine centers. Failure was observed in 389 (68%) patients during the observation period. The median follow up of all patients was 30.9 months, and the median failure-free survival was 9.8 months (63% at 6 months, 45% at 1 year, and 29% at 2 years). Of the variables measured at enrollment, ten were associated with shorter failure-free survival: higher National Institutes of Health 0–3 skin score, higher National Institutes of Health 0–3 gastrointestinal score, worse range of motion summary score, lower forced vital capacity (%), bronchiolitis obliterans syndrome, worse quality of life, moderate to severe hepatic dysfunction, absence of treatment for gastric acid, female donor for male recipient, and prior grade II–IV acute graft-versus-host disease. Addition of a new systemic treatment, the major cause of failure, was associated with an increased risk of subsequent non-relapse mortality (hazard ratio=2.06, 95% confidence interval: 1.29–3.32; P<0.003) and decreased survival (hazard ratio=1.51, 95% confidence interval: 1.04–2.18; P<0.03). These results show that fewer than half of patients on systemic treatment will be failure-free survivors at 1 year, and fewer than a third will reach 2 years without experiencing failure. Better treatments are needed for chronic graft-versus-host disease. Clinicaltrials.gov identifier: . NCT00637689相似文献
85.
To assess the effects of long-term nasal continuous positive airway pressure (CPAP) in occlusive sleep apnea syndrome (OSA), 17 patients with severe symptomatic OSA had repeated spirometry, arterial blood gases, and nocturnal polysomnograms off nasal CPAP after 3 to 46 months of treatment with nasal CPAP. Without loss of weight or change in respiratory mechanics, the ventilatory disturbance index fell from a mean of 87 events per hour to 57 events per hour (p < 0.0001), correlating with an improvement in mean nocturnal desaturation with sleep-disordered breathing events (r = 0.54, p = 0.03). Moreover, the daytime PaO2 rose significantly from a mean of 69 mm Hg to a mean of 82 mm Hg (P = 0.0001) at follow-up. The rise in daytime PaO2 was not only due to the alleviation of daytime hypercapnea observed in eight of nine hypercapneic subjects since the P(A-a)O2 gradient also decreased significantly. The improvement in PaO2 correlated significantly with the number of months of CPAP therapy, suggesting a continuing effect over time (r = 0.58, p = 0.015). These results indicate that there is a reversible element of the severity of OSA and suggest a result of nasal CPAP therapy may be to reverse the adverse and time-dependent effects of hypoxemia and sleep fragmentation on ventilatory control in severe OSA. 相似文献
86.
Epstein-Barr virus lymphoproliferation after bone marrow transplantation 总被引:16,自引:7,他引:16
We review 15 cases of secondary B-cell lymphoproliferative disorders that occurred among 2,475 patients who received allogeneic bone marrow transplants (BMTs) at the Fred Hutchinson Cancer Research Center (Seattle) between 1969 and 1987. The histopathologic findings in 14 of the 15 patients spanned a wide spectrum of lymphoproliferative lesions. One patient had features characteristic of angioimmunoblastic lymphadenopathy. Epstein-Barr virus (EBV) genomic sequences were identified by Southern blot analysis in each of the 13 patients evaluated. Ten of the 12 lesions evaluated originated in donor cells. In two patients, who had mixed chimerism after transplantation, the lesions originated in host cells. The combined evidence from immunoglobulin light chain staining and the analysis of immunoglobulin heavy chain gene rearrangement indicated that the lesions in most patients represented polyclonal proliferations that gave rise to clonal subpopulations. The results indicate an overall actuarial incidence of 0.6% for this complication in BMT recipients. Anti-CD3 monoclonal antibody (MoAb) treatment of acute graft-v-host disease (GVHD) and T cell depletion of the donor marrow were statistically significant risk factors, and GVHD appeared to play a contributing role, particularly in the setting of human leukocyte antigen (HLA) disparity. Two patients had no identifiable risk factors. Prophylaxis or treatment with acyclovir had no detectable effect in the patients; all but two died with uncontrolled lymphoproliferation. 相似文献
87.
Monoclonal antibody BA-1 binds to B lymphocytes, to cells from most cases of non-T acute lymphoblastic leukemia (ALL), and weakly to neutrophils. To determine whether BA-1 also reacts with hematopoietic progenitor cells (HPC), we studied the effect of removal of BA-1+ cells from human bone marrow on the proliferation in vitro of the trilineage precursor cell CFU-GEMM, and on the committed progenitor cells of granulopoiesis (CFU-C) and erythropoiesis (BFU-E/CFU-E). Complement- mediated cytotoxicity using BA-1 at concentrations far beyond those required to lyse BA-1+ bone marrow cells and ALL cells did not result in inhibition of colony formation in any of the assays. A rosette separation method, using ox red blood cells coated with BA-1, resulted in enrichment of HPC in the BA-1-depleted interface, whereas very few HPC were found in the BA-1-enriched pellet. Both methods indicate that BA-1 does not bind to HPC, although binding of the antibody to the lymphohematopoietic stem cell cannot be excluded yet. The high cytotoxic capacity of the IgM antibody BA-1, and the lack of reactivity with HPC, make the antibody particularly suitable for use in autologous bone marrow transplantation for patients with ALL. 相似文献
88.
Deeg HJ; Storb R; Thomas ED; Appelbaum F; Buckner CD; Clift RA; Doney K; Johnson L; Sanders JE; Stewart P; Sullivan KM; Witherspoon RP 《Blood》1983,61(5):954-959
Eight patients with Fanconi's anemia were given cyclophosphamide alone (seven patients) or combined with procarbazine and antithymocyte globulin (one patient) followed by marrow grafts from HLA-identical siblings. All patients had engraftment. Seven developed acute and three chronic graft-versus-host disease (GVHD). Three patients died with GVHD and infectious complications (days 19, 56, and 82) and one with an intracerebral hemorrhage (day 540). Four patients are surviving 647- 3435 days after grafting, two are well, and two have chronic GVHD that is improving. These results show that Fanconi's anemia can be treated successfully by allogeneic marrow transplantation. 相似文献
89.
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression 总被引:18,自引:26,他引:18
Sullivan KM; Shulman HM; Storb R; Weiden PL; Witherspoon RP; McDonald GB; Schubert MM; Atkinson K; Thomas ED 《Blood》1981,57(2):267-276
Fifty-two of 175 (30%) survivors of allogeneic marrow transplantation developed chronic graft-versus-hose diseases (GVHD). Five with limited chronic GVHD had an indolent clinical course with involvement of only the skin and liver. Forty-seven with extensive chronic GVHD had an unfavorable multiorgan disorder that resembled several autoimmune diseases. Thirteen patients with extensive disease (group I) were not treated and only 2 survive with Karnofsky scores >- 70%. Mortality resulted from infections and morbidity from sica syndrome, pulmonary and hepatic insufficiency, scleroderma-like skin disease, and contractures. Another 13 (group II) received a median of 8 mo prednisone and/or a brief course of antithymocyte globulin, and 3 survive without disability. The other 21 (group III) were treated with a combination of prednisone (1.0 mg/kg/q.o.d.) and either cyclophosphamide, procarbazine, or azathioprine (all 1.5 mg/kg/day) for a median of 13 mo. Combination therapy was well tolerated with only modest myelotoxicity. Fifteen in group III had a good and 4 a fair response to treatment while 2 with no response died. Azathioprine and prednisone was the most effective regimen. All therapy has been discontinued in 12 group III patients: GVHD returned in 5 (including 2 who died in spite of retreatment) while 7 remain free of GVHD for a median of 11 (range 6-30) mo observation. Only I group III survivor is disabled and 16 of the original 21 are alive 2-4 yr after transplant with Karnofsky scores of 70%-100%. Thus, combination immmunosuppression appears to favorably affect and, in some cases, premanently arrest the adverse natural course of extensive chronic GVHD. 相似文献
90.
The prevalence of and risk factors for hypertension were determined among habitants in the European side of Istanbul who are 25 years and older. Eight administrative districts were selected with the method of simple random sampling. The participants were selected through systematic calling from address lists. Between 17 and 22 June 2002, the questionnaires were applied to the participants in a face-to-face interview; then arterial blood pressures, body weights and heights of the participants were measured. Of 423 adults participating in the study, 35.5% were hypertensive; 35.9% were obese, 27.9% were overweight and 2.1% were underweight. Risk factors for hypertension such as age, gender, educational status, social security, family history of hypertension and cardiovascular disease, medical history of diabetes and congestive heart failure, smoking and alcohol use, and body mass index in the hypertensive and non-hypertensive groups were investigated by means of logistic regression analysis. Age [odds ratio (OR): 5.20, 95% confidence interval (CI): 2.18-12.40], body mass index (OR: 2.22, 95% CI: 1.57-3.16) and smoking (OR: 0.72, 95% CI: 0.55-0.95) were found to be correlated with hypertension. The results showed that the prevalence of hypertension was high in Istanbul, and obesity, being overweight and advanced age were the risk factors for hypertension. 相似文献